HECTD3 mediates an HSP90-dependent degradation pathway for protein kinase clients by Li, Zhaobo et al.
ArticleHECTD3 Mediates an HSP90-Dependent
Degradation Pathway for Protein Kinase ClientsGraphical AbstractHighlightsd siRNA screen identifies factors regulating HSP90-directed
client degradation
d HECTD3 promotes CRAF degradation after HSP90 ATPase
inhibition
d HECTD3 interacts with HSP90-CDC37-CRAF via its DOC
domain
d CRAF-dependent tumor cells downregulate HECTD3 E3
ligase activityLi et al., 2017, Cell Reports 19, 2515–2528
June 20, 2017 ª 2017 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2017.05.078Authors
Zhaobo Li, Lihong Zhou,
Chrisostomos Prodromou, Velibor Savic,
Laurence H. Pearl
Correspondence
laurence.pearl@sussex.ac.uk
In Brief
Li et al. develop a cellular assay for
HSP90-inhibitor-triggered degradation of
protein kinase clients and screen for
components of the ubiquitin/proteasome
system that mediate this. They identify
HECTD3 as an E3 ligase that directs
CRAF degradation and demonstrate its
interaction with HSP90/kinase
complexes via its DOC domain.
Cell Reports
ArticleHECTD3 Mediates an HSP90-Dependent
Degradation Pathway for Protein Kinase Clients
Zhaobo Li,1 Lihong Zhou,1 Chrisostomos Prodromou,1 Velibor Savic,1,2,3 and Laurence H. Pearl1,4,*
1Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9QR, UK
2Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton BN1 9PX, UK
3Present address: Horizon Discovery, 8100 Cambridge Research Park, Waterbeach, Cambridge CB25 9TL, UK
4Lead Contact
*Correspondence: laurence.pearl@sussex.ac.uk
http://dx.doi.org/10.1016/j.celrep.2017.05.078SUMMARY
Inhibition of the ATPase cycle of the HSP90 chap-
erone promotes ubiquitylation and proteasomal
degradation of its client proteins, which include
many oncogenic protein kinases. This provides the
rationale for HSP90 inhibitors as cancer therapeu-
tics. However, the mechanism by which HSP90
ATPase inhibition triggers ubiquitylation is not under-
stood, and the E3 ubiquitin ligases involved are
largely unknown. Using a siRNA screen, we have
identified components of two independent degrada-
tion pathways for the HSP90 client kinase CRAF. The
first requires CUL5, Elongin B, and Elongin C, while
the second requires the E3 ligase HECTD3, which is
also involved in the degradation of MASTL and
LKB1. HECTD3 associates with HSP90 and CRAF in
cells via its N-terminal DOC domain, which is muta-
tionally disrupted in tumor cells with activated MAP
kinase signaling. Our data implicate HECTD3 as a
tumor suppressor modulating the activity of this
important oncogenic signaling pathway.INTRODUCTION
The HSP90 molecular chaperone is responsible for the stabiliza-
tion and biological activity of a diverse set of ‘‘clients,’’ including
clinically important proteins such as nuclear hormone receptors
and a broad range of protein kinases (Taipale et al., 2010). The
involvement of the HSP90 (heat shock protein 90) system in
the cellular stabilization of oncogenic protein kinases such as
ErbB2, BRaf-V600E, FGFR-G719S, BCR-ABL, and EML4-ALK
has marked it as a prime target for drug discovery, and a number
of potent HSP90 inhibitors are at various stages of clinical trial in
a range of tumor types (Neckers and Workman, 2012). These
compounds act as competitive inhibitors of ATP binding to
the N-terminal domain of the chaperone molecule, blocking
the ATPase-coupled conformational cycle that is essential for
HSP90s activity (Ali et al., 2006; Panaretou et al., 1998; Prodro-
mou et al., 2000).Cell
This is an open access article undEarly studies showed that client proteins such as CRAF and
ErbB2 become ubiquitylated and degraded by the proteasome
in cells treated with the natural-product HSP90 inhibitor gelda-
namycin (Chavany et al., 1996; Schulte et al., 1995), even before
its biochemical mode of action as an ATP-competitive inhibitor
was revealed (Prodromou et al., 1997; Roe et al., 1999). This
phenomenon has been robustly repeated for many HSP90-
dependent protein kinases using a range of different inhibitor
chemotypes (Banerji et al., 2005; Chiosis et al., 2001; Sharp
and Workman, 2006; Sharp et al., 2007) and is widely accepted
as the hallmark of an HSP90 client protein. Protein kinase clients
of HSP90 are also ubiquitylated and degraded when their inter-
action with the HSP90 co-chaperone CDC37, and consequent
recruitment to the HSP90 machinery, is blocked by ATP-
competitive protein kinase inhibitors (Polier et al., 2013).Whether
this proceeds through the same pathway as the HSP90-inhibi-
tor-triggered degradation is uncertain.
Ubiquitylation involves a cascade of enzymatic reactions,
starting with the ATP-dependent activation of ubiquitin by
the E1-activating enzyme and its covalent attachment to an
E2-conjugating enzyme via a thioester bond connecting the
a-carboxyl at the C terminus of ubiquitin and a cysteine side
chain of the E2. Transfer of ubiquitin from the E2-ubiquitin (E2-
Ub) conjugate to the target protein is catalyzed by an E3 ubiquitin
ligase enzyme. E3 enzymes provide the target specificity of the
ubiquitylation process and encapsulate the ability to recognize
a specific feature of the target protein—the degron—that marks
it for modification.
While a number of E3 ligases, such as CHIP and cullin-RING
ubiquitin ligases (CRLs) based upon CUL5, have been impli-
cated, there is no consensus on the pathway by which HSP90-
dependent client proteins become ubiquitylated and targeted
for degradation. In particular, there is no understanding of the na-
ture of the degron presented by the target protein in the context
of a complex with HSP90 in which the chaperone ATPase cycle
is inhibited or when the target protein is deprived of chaperone
interaction by an ATP-competitive kinase inhibitor.
To gain further insight into these questions, we have devel-
oped a cell-based HSP90 client protein degradation assay that
is amenable to high-throughput screening, and we have per-
formed a focused siRNA (small interfering RNA) screen of com-
ponents of the cellular ubiquitylation system, in order to identify
the factors involved. Our data confirm a role for CUL5-basedReports 19, 2515–2528, June 20, 2017 ª 2017 The Author(s). 2515
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. HSP90-Dependent Degradation of
eYFP-CRAF Fusion Protein
(A) eYFP-CRAF stably transfected into HEK293
retains the cytoplasmic distribution displayed by
endogenous CRAF. Scale bar, 50 mm.
(B) eYFP-CRAF transfected into HEK293 ex-
presses a stable full-length protein with no
detectable free eYFP, so that all cellular fluores-
cence can be attributed to levels of the fusion
protein.
(C) eYFP-CRAF, like endogenous CRAF, is
degraded in HEK293 cells following treatment
with the HSP90 ATPase inhibitor AUY922.
(D) Treatment of transfected cells with AUY922
promotes ubiquitylation of eYFP-CRAF, as visu-
alized in an anti-ubiquitin western blot. The levels
of ubiqutylated protein detected are enhanced by
the proteasome inhibitor MG132. These data
confirm that eYFP-CRAF is degraded in the same
way as previously shown for endogenous CRAF.
(E) Treatment of transfected cellswithAUY922over
8 hr gives an 50% reduction in relative fluores-
cence intensity of transfected cells compared with
untreated cells. Error bars show SD.systems but identify amajor new route for HSP90 client degrada-
tion via a member of the HECT-domain family of E3 ligases.
RESULTS
Client protein degradation following pharmacological inhibition
of HSP90 can be followed by immunoblots of cell lysates. How-
ever, this format is only suitable for determining the involvement
of a limited number of candidate genes. Therefore, we set out to
develop an assay format in which degradation of a client protein
could be monitored in a highly parallel fashion suitable for use in2516 Cell Reports 19, 2515–2528, June 20, 2017a broad siRNA screen of the components
of the ubiquitin-proteasome system.
A Fluorescence-Based Assay for
Client Protein Degradation
The proto-oncogene kinases BRAF and
CRAF are well-documented HSP90 client
proteins that have previously been shown
to be ubiquitylated and degraded in
tumor cell lines treated with the HSP90
inhibitor AUY922 (Sharp et al., 2007).
However, AUY922, like other HSP90 in-
hibitors, strongly inhibits cell growth and
also promotes apoptosis in tumor cell
lines such as HT29 and HCT116, which
are addicted to mitogen-activated pro-
tein kinase (MAPK) signaling mediated
by RAF kinases, potentially confounding
reliable measurement of protein levels.
Furthermore, tumor cells are likely to
have highly perturbed protein degrada-
tion pathways that reflect their idiosyn-
cratic growth requirements. Therefore,we explored a number of alternatives and settled on HEK293
cells, which are virally immortalized non-cancer cells not known
to be dependent on MAPK signaling for survival and growth. For
facile measurement of client protein levels, we explored a num-
ber of reporter constructs in which a fluorescent protein was
fused to BRAF, CRAF, or their isolated kinase domains. We
found that full-length CRAF with an N-terminal enhanced yellow
fluorescent protein (eYFP) fusion (Experimental Procedures)
could be stably expressed at visible levels in HEK293 cells (Fig-
ures 1A and 1B) and displayed a sub-cellular distribution similar
to that of endogenous CRAF in the absence of oncogenic RAS
(legend on next page)
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(Marais et al., 1997). Expression of the eYFP-CRAF fusion had no
effect on the concentration of AUY922 that gave 50% growth in-
hibition (GI50) in the HEK293 cells, indicating that the expression
of the eYFP-CRAF fusion was neither toxic nor mitogenic (Fig-
ure S1A). We also determined a concentration of AUY922 (3 3
GI50) that, while substantially decreasing cell growth relative to
untreated cells, did not cause any decrease in total cell count
over a 72-hr incubation period. This concentration also had virtu-
ally no effect on cell viability after 12 hr; therefore, we settled on
this concentration (3 3 GI50) in all subsequent assays (Figures
S1B and S1C). We observed a substantial decrease compared
to control in levels of both endogenous CRAF and the eYFP-
CRAF fusion protein at time points between 8 and 24 hr after
treatment of transfected cells with AUY922 at this concentration
(Figure 1C). Consistent with this, eYFP-CRAF protein immuno-
precipitated from cells treated with AUY922 cross-reacted with
an anti-ubiquitin antibody, and this was substantially enhanced
by the addition of the proteasome inhibitor MG132 (Figure 1D).
Taken together these data confirm that the addition of the N-ter-
minal eYFP did not interfere with the well-described HSP90-
associated and ubiquitin-dependent degradation of CRAF
following HSP90 inhibition. Finally, we measured the effect of
treatment with AUY922 at our standardized dose on the fluores-
cence signal intensity of the eYFP-CRAF stably transfected cells,
and we found a reproducible 50% decrease in intensity over
8 hr relative to untreated cells (Figure 1E). This was consistent
with the loss of signal in the western blots and sufficient to
provide a robust and quantitativemeasure of drug-triggered pro-
tein degradation in viable cells that is amenable to automated
screening.
siRNA Screen for Mediators of CRAF Degradation
The HEK293 cells stably expressing eYFP-CRAF were screened
against a siRNA library (Dharmacon) directed against all human
E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating en-
zymes, and components of CRLs and HECT E3 ubiquitin ligase
systems, among others. Degradation of eYFP-CRAF was initi-
ated by the addition of AUY922, and experimental values were
determined by measuring the change in fluorescence intensity
in the treated cells over 8 hr (see Experimental Procedures).
Geneswere ranked by the relative stabilization of fluorescence
following AUY922 treatment when expression of the encoded
protein was knocked down, compared to the level following
AUY922 treatment in the presence of a non-targeting control
siRNA (see Experimental Procedures) (Figure 2A; Table S1).
Of the 87 genes tested, 10 stabilized eYFP-CRAF by 15% orFigure 2. siRNA Screen for Factors Mediating eYFP-CRAF Degradatio
(A) Waterfall plot of siRNA-targeted genes (horizontal) versus the stabilization of fl
treated with AUY922 relative to treated cells transfected with a control siRNA.
(B) Repeat siRNA knockdowns of ‘‘hits’’ identified in (A); knockdown of HECTD3, C
gave robust and reproducible stabilization of eYFP-CRAF on AUY922 treatment. M
indicate SD. Stabilization relative to control following knockdown of HECTD3, CU
and p = 0.001 for UBA1).
(C) Same as in (B), but comparing the siRNA knockdown of CUL5 (same data as in
siRNA control. Knockdown of the accessory scaffold components TCEB1 (also kn
to a degree comparable to that of CUL5 (p = 0.00015 for TCEB1, and p = 0.00017
ligase complexes. However, none of the SOCS proteins gave comparable stabiliz
replicates and error bars show SD.
2518 Cell Reports 19, 2515–2528, June 20, 2017greater, compared with the control. Among these were the
E1 ubiquitin-activating enzymes UBE1 (also known as UBA1)
and UBE1L2, as well as the ubiquitin-like protein E1 enzyme
UBE1DC1. As E1 enzymes are required for all ubiquitylation
processes, the identification of UBE1 as a factor making a sub-
stantial contribution to CRAF degradation provides a critically
important positive control that validates the screen. Three E2
ubiquitin-conjugating enzymes also feature among the highest
ranked genes: UBE2D3 (also known as UbcH5C), which can
act as an initiator of ubiquitin chains and in K11 and K48-specific
chain elongation (UniProt: P61077); UBE2G1 (also known as
Ubc7), which catalyzes K48 or K63 chain elongation (UniProt:
P62253); and UBE2E1 (UbcH6), which catalyzes K48 chain elon-
gation (UniProt: P51965). Components of four E3 ligase systems
also featured in the ten highest ranked genes. These include
CUL5, the core scaffold of a large group of CRLs (Lydeard
et al., 2013); TSG101, a ubiquitin-binding component of the
ESCRT1 system (Zhang et al., 2014); and two HECT-domain
E3 ligases—NEDD4, implicated in the regulation of a range of
membrane-associated signaling proteins and ion channels
(Zou et al., 2015), and HECTD3, whose biology is, as yet, poorly
defined.
Involvement of CUL5 and HECTD3
To verify the involvement of these genes in mediating HSP90-
associated and ubiquitin-dependent degradation of eYFP-
CRAF, we repeated the fluorescence stabilization assays with
individually designed siRNAs distinct from the pools used in
the screens. None of the E2s in the top-ten hits from the original
screen gave stabilization of eYFP-CRAF >10% when knocked
down in the repeat experiments, nor did the repeat siRNA knock-
down of the E3 NEDD4. However, repeat siRNA knockdown of
CUL5 or HECTD3 caused robust, repeatable, and statistically
highly significant (p < 0.0001 in paired t test) stabilization of
eYFP-CRAF fluorescence at levels comparable to that obtained
with repeat siRNA knockdown of UBE1 (Figure 2B). Knockdown
of the HSP90/HSP70-associated U-box E3 ligase CHIP/STUB1,
which has previously been implicated in HSP90-inhibitor-trig-
gered degradation of ErbB2 (Xu et al., 2002; Zhou et al., 2003)
and a range of other ubiquitylation events (Edkins, 2015), had
no significant effect (p > 0.1 in paired t test) on the stability of
eYFP-CRAF in this system.
HECTD3, which gave the strongest signal in the initial screen,
belongs to a class of E3 ubiquitin ligases in which substrate
recognition, E2 recruitment, and catalytic activity are often
encapsulated in a single polypeptide chain (Rotin and Kumar,n
uorescence in cells expressing eYFP-CRAF transfected with test siRNAs and
UL5, and UBA1 (also known as UBE1) using different siRNAs from those in (A)
easurements are averages of four (UBA1 only) or six replicates, and error bars
L5, and UBA1 is significant in a paired t test (p < 0.0001 for HECTD3 and CUL5,
B) with the knockdown of known CUL5 CRL complex components, relative to
own as Elongin C) and TCEB2 (also known as Elongin B) stabilized eYFP-CRAF
for TCEB2), consistent with their essential involvement in CUL5-based CRL E3
ation (all significant measurements at least p < 0.01). Values are averages of six
Figure 3. Kinase Specificity of HECTD3
(A)Western blot of endogenous CRAF in HEK293 cell lysates following 24-hr treatment with AUY922. Substantial degradation is observed in cells transfected with
control siRNA, but CRAF levels are stabilized in cells transfected with siRNA against HECTD3. Both immunoreactive bands to the HECTD3 antibody are knocked
down by the siRNA; see below. GAPDH levels provide a loading control.
(B)Western blots of knownHSP90 protein kinase clients in HEK293 lysates and their response to treatment of cells with AUY922. Levels of ErbB2, MASTL, CRAF,
LKB1, and CDK4, but not BRAF or PDK1, decrease in response to HSP90 inhibition.
(legend continued on next page)
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2009). CUL5, however, is the common core ‘‘scaffold’’ compo-
nent of a family of multiprotein complexes, the Elongin BC-
CUL2/5-SOCS-box (ECS) E3 ubiquitin ligases, where it provides
the binding sites for a catalytic RING finger protein (RBX1 or
RBX2) required for Ubq-E2 recruitment and for the TCEB2-
TCEB1 (also known as Elongin B-Elongin C) heterodimer. This
latter mediates recruitment of one of seven SOCS-box-contain-
ing proteins that provide specificity for individual ubiquitination
substrates of this E3 system (Lydeard et al., 2013). Consistent
with the involvement of CUL5 in eYFP-CRAF degradation, but
in contradiction to earlier studies in tumor cell lines that impli-
cated CUL5 in HSP90 client protein degradation (Ehrlich et al.,
2009; Samant et al., 2014) independently of TCEB1/2, we found
that siRNA knockdown of the CUL5 partner scaffold proteins
TCEB2 and, to a lesser degree, TCEB1 also elicited substantial
stabilization of eYFP-CRAF fluorescence. However, none of
the seven SOCS-box proteins gave a comparable signal to
knockdown of the TCEB1/2 proteins that recruit them, although
siRNA knockdown of both SOCS1 and SOCS4 stabilized eYFP-
CRAF fluorescence by 20% (Figure 2C). These data suggest
that eYFP-CRAF degradation by this system is mediated by a
conventional CUL5-TCEB1/2 core, but with target selectivity
either provided redundantly by multiple SOCS-box proteins
or by as-yet-unidentified proteins that are recruited via the
TCEB1/2 (Elongin B/C) adaptor scaffold.
Client Protein Specificity of HECTD3
Although the eYFP N-terminal fusion did not affect the suscepti-
bility of CRAF to HSP90-associated degradation, we wanted to
eliminate the possibility that the poorly characterized HECTD3
E3 ligase identified by the screen, and subsequently confirmed
in individual experiments, reflects an idiosyncratic feature of
the eYFP fusion protein rather than specificity for the CRAF ki-
nase itself. By western blot, we observed robust degradation
of endogenous native CRAF in untransformed HEK293 cells
treated with control siRNA 24 hr after the addition of AUY922,
but this was substantially reduced in cells in which HECTD3
was knocked down, confirming that endogenous CRAF is a
bona fide degradation target of HECTD3 (Figure 3A).
We also wanted to determine whether CRAF was the only
HSP90 protein kinase client whose degradation was mediated
by HECTD3. We immunoblotted HEK293 cells for a range of
documented HSP90 protein kinase clients in addition to CRAF
and found that ErbB2, BRAF, MASTL, LKB1, PDK1, and CDK4
were all expressed at detectable levels in HEK293 cells. Of
these, we observed robust degradation of ErbB2, MASTL,
LKB1, and CDK4 when cells were treated with AUY922 at the
same exposure used for CRAF, albeit with different kinetics for
the individual proteins. PDK1 and BRAF, which is wild-type in
HEK293 cells, were not noticeably degraded over a 24-hr period
under the same conditions (Figure 3B). siRNA knockdown of
HECTD3 diminished HSP90-inhibitor-triggered degradation of(C) MASTL, LKB1, and CRAF degradation following AUY922 treatment is reduce
siRNA. Knockdown of HECTD3 had no clear effect on AUY922-triggered degrada
GAPDH is a loading control for each.
(D)Western blot of eYFP-CRAF immunoprecipitated from cell lysates of HEK293 c
CRAF can be enhanced in HEK293 cell lysates, as well as in intact cells, by the a
2520 Cell Reports 19, 2515–2528, June 20, 2017LKB1 and MASTL, albeit to a lesser degree than CRAF, but
had little effect on degradation of CDK4 and ErbB2 (Figure 3C).
Interestingly, drug-induced ubiquitylation of CRAF did not
require intact cells and could be observed in lysates from
HEK293 cells expressing eYFP-CRAF on the addition of
AUY922 in a dose-dependent fashion (Figure 3D).
Kinase-Inhibitor-Dependent Degradation
We previously showed that ATP-competitive kinase inhibitors
block the association of a range of protein kinase clients with
the kinase-specific co-chaperone CDC37 and thereby deprive
them of access to the HSP90 chaperone system, resulting in
their ubiquitylation and degradation (Polier et al., 2013). Whether
this HSP90-independent pathway of client degradation oper-
ates through the same mechanism as the HSP90-dependent
pathway is currently unknown.
Treatment of HEK293 cells with sorafenib substantially in-
hibited MAPK pathway signaling and promoted some degrada-
tion of eYFP-CRAF over 24 hr, although to a much smaller
degree than in our previous observations for (1) vemurafenib
and BRAFV600E, (2) lapatinib and ErbB2, and (3) erlotinib and
EGFRG719S (Polier et al., 2013) in tumor cells (Figure S2A).
Knockdown of HECTD3 in these cells had little effect on this
response to sorafenib, compared with treatment with a control
siRNA, suggesting that HECTD3 probably does not play a major
role in the kinase degradation pathway triggered by chaperone
deprivation due to kinase inhibitor blockade of CDC37 binding.
Finally, we sought to determine whether HECTD3 is involved in
general CRAF turnover in unstressed conditions where there is
full access to a functional CDC37/HSP90 chaperone system.
HEK293 cells expressing eYFP-CRAF were pulse labeled with
the methionine mimetic azidohomoalanine and lysed at different
times post-labeling (see Experimental Procedures). Labeled pro-
tein was tagged with biotin using a CLICK reaction, and eYFP-
CRAF was immunoprecipitated and visualized in an anti-biotin
western blot (Figure S2B). We observed little difference in the
progressive decrease in detectable levels of biotin-labeled
eYFP-CRAF over time between cells treatedwith a control siRNA
or with siRNA directed against HECTD3. This shows that, while
HECTD3 is a significant player in CRAF degradation in the
context of HSP90, it does not play a major role in overall CRAF
proteostasis in unstressed conditions.
HECTD3, HSP90, and CRAF Interaction
Our siRNA data strongly implicate HECTD3 as a specific
component of the HSP90-associated, ubiquitin-dependent
proteasomal degradation pathway for CRAF in HEK293 cells.
However, they do not define whether HECTD3 is involved
directly in the recognition and ubiquitylation of CRAF in the
context of inhibited HSP90 or whether it is a downstream fac-
tor whose influence is indirect. To gain some insight into this,
we established a cellular proximity ligation assay (Duolink,d in HEK293 cells transfected with siRNA to HECTD3 compared to a control
tion of ErbB2 or CDK4. The panel is a montage of three separate experiments;
ells treatedwith increasing doses of AUY922 post-lysis. Ubiquitylation of eYFP-
ddition of AUY922 in a dose-dependent fashion.
(legend on next page)
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Sigma-Aldrich; see Experimental Procedures), which gener-
ates a fluorescent focus when two target proteins are within
30–40 nm of each other within the cell, and we used this to
determine whether HECTD3 co-localizes with HSP90 and/or
CRAF. As a negative control, we looked at the proximity of
endogenous HSP90 with overexpressed eYFP in HEK293
cells. As these two abundant proteins are not expected to
interact, this provides a control for the background noise of
the proximity ligation assay (PLA) system, and very few foci
were detectable in untreated cells or cells treated with
AUY922 for 18 hr (Figure S3). In contrast, the known interact-
ing proteins HSP90 and CRAF gave a strong proximity signal
(Figure 4A), which dropped by nearly half after 18-hr treatment
with AUY922, reflecting the depletion of CRAF we observed
in treated cells at that time point. A proximity signal was
also observed between CRAF and HECTD3 in untreated cells,
but this more than doubled in cells treated for 18 hr with
AUY922, indicating a large increase in proximity between
HECTD3 and CRAF following HSP90 inhibition. This increase
in co-localized HECTD3 and CRAF is all the more significant,
given the substantial decrease in total cellular CRAF that treat-
ment with the HSP90 inhibitor elicits (Figure 3). A comparably
significant increase in proximity between HECTD3 and HSP90
was also observed following drug treatment (Figure 4B).
HECTD3 could also be detected in western blots following
immunoprecipitation of eYFP-CRAF from treated cells,
with the signal decreasing, as eYFP-CRAF is progressively
degraded (Figure 4C). To confirm the HECTD3-CRAF interac-
tion, we constructed stable HEK293 lines expressing either a
HECTD3-eYFP or an eYFP-HECTD3 fusion protein, or eYFP
alone, and used these to co-immunoprecipitate associated
proteins. We observed robust specific co-immunoprecipitation
of HSP90, the kinase-specific co-chaperone CDC37, and
endogenous CRAF with both of the HECTD3 constructs, but
not with eYFP alone (Figure 4D). Consistent with the HSP90-in-
hibitor-dependent ubiquitylation and degradation of CRAF,
the levels of HSP90 and CDC37 co-immunoprecipitated with
HECTD3 increased with increasing exposure of the cells to
AUY922, while the levels of CRAF recovered decreased in
line with its progressive degradation. Taken together, these
data show that HECTD3 is brought into close physical prox-
imity in cells with both HSP90 and CRAF, as part of the
HSP90-inhibitor-induced ubiquitylation and degradation of
CRAF, and is most likely involved in a physical complex withFigure 4. Cellular Association of HSP90, CRAF, and HECTD3
(A) Combined differential interference contrast (Nomarski)/fluorescence image of
localized HSP90 andCRAF are visualized as red foci generated by a rolling circle a
shows a 53 digital zoom of the left panel.
(B) Histogram of average PLA foci per cell from analysis of cells before and after
eYFP and endogenous HSP90 was measured in cells expressing eYFP and prov
transfected HEK293 cells. Values are averages of eight fields and error bars sho
(C) Western blot of immunoprecipitated eYFP-CRAF from HEK293 cells showing
as eYFP-CRAF is degraded following treatment with AUY922.
(D) Western blots of HSP90, CRAF, and CDC37 co-immunprecipitated from HEK
(see Experimental Procedures). Levels of HSP90 and CDC37 co-immunoprecipi
HSP90 CRAF or CDC37 was co-immunoprecipitated from cells expressing eY
treatment with AUY922. GFP immunoreactivity provides a common loading cont
See also Figure S3.
2522 Cell Reports 19, 2515–2528, June 20, 2017both proteins. The persistence of CDC37 in association with
HECTD3 and HSP90 following drug treatment is in contrast
with previous observations of CUL5, whose presence in kinase
immunoprecipitates involving HSP90 was found to coincide
with the loss of CDC37 (Samant et al., 2014).
HECTD3 DOC Domain Mediates CRAF/HSP90
Interaction
HECTD3 has a unique architecture among the HECT-domain E3
ubiquitin ligases (Rotin and Kumar, 2009). Apart from the highly
conserved catalytic HECT domain (Marı´n, 2010) at the C termi-
nus, the only identifiable feature in the HECTD3 amino acid
sequence is a DOCdomain in theN-terminal region of the protein
(Figure 5A). DOC domains also occur in the APC10 subunit of the
anaphase-promoting complex (da Fonseca et al., 2011) and in
the atypical cullin proteins CUL7 and CUL9 (Dias et al., 2002).
To define which regions of HECTD3 are required for interac-
tion with its CRAF ubiquitylation substrate, we developed
recombinant expression systems for full-length HECTD3
and for constructs of the isolated DOC and HECT domains
(see Experimental Procedures) (Figure 5B). Full-length His6-
HECTD3, added to lysates from HEK293 cells expressing
the eYFP-CRAF fusion protein, was robustly co-immunopre-
cipitated by anti-eYFP antibodies, whereas no His6-HECTD3
was co-immunoprecipitated when added to cells only ex-
pressing eYFP (Figure 5C). A GST (glutathione S-transferase)
fusion of the isolated HECTD3-DOC (GST-DOC) domain could
also be co-immunoprecipitated from HEK293 cells expressing
eYFP-CRAF, whereas a GST fusion of the isolated HECTD3-
HECT (GST-HECT) domain was not. In the reverse experi-
ment, GST-DOC added to a HEK293 cell lysate was able to
co-precipitate endogenous CRAF and associated HSP90 (Fig-
ure 5D). These data strongly implicate the DOC domain as
a key determinant of the interaction of HECTD3 with CRAF
and HSP90.
HECTD3 Isoforms and Cell Line Variability
Unlike HEK293 cells, tumor cell lines such as HCT116 and HT29,
in which HSP90-inhibitor-triggered client protein degradation
has been previously studied, are dependent on intense signaling
through the MAPK cascade. This, in turn, is critically dependent
on the activity of the HSP90 clients CRAF and/or BRAF-V600E
(Ehrlich et al., 2009; Samant et al., 2014). Consequently, it is likely
that such tumor cells will have adapted to decrease the influencefield of untreated HEK293 cells. Cell nuclei are indicated in blue (DAPI), and co-
mplification PLA (see Experimental Procedures). Scale bars, 50 mm.Right panel
treatment with AUY922 for the protein pairs indicated (Figure S3). Proximity of
ides a control for the non-specific signal; all other measurements were in un-
w SD; *p > 0.05; **p% 0.01; ****p% 0.0001.
co-immunoprecipitation of HECTD3. The levels of recovered HECTD3 diminish
293 cells expressing eYFP-HECTD3, HECTD3-eYFP, or eYFP, with GFP-trap
tated with the HECTD3 constructs increase with length of drug exposure. No
FP only. The levels of recovered CRAF diminish as it is degraded following
rol.
Figure 5. The DOC Domain of HECTD3 Me-
diates Substrate Interaction
(A) Schematic of the domain architecture of
HECTD3. Only two defined domains can be
recognized: the C-terminal catalytic HECT domain
common to all members of the HECT E3 ubiquitin
ligase family and a DOC domain homologous to
APC10, which occurs midway through the N-ter-
minal region.
(B) Coomassie-stained SDS-PAGE of purified re-
combinant HECTD3 constructs: His6-tagged full-
length HECTD3 and GST fusions of the isolated
DOC and HECT domains. M, molecular weight, in
kilodaltons.
(C) Top: lysates from HEK293 cells expressing
either eYFP or eYFP-CRAF were incubated with
purified HECTD3 constructs as in (A), subjected to
immunoprecipitation using GFP-Trap (Experi-
mental Procedures), and analyzed by western blot
using a-His (left) or a-GST (right). Full-length
HECTD3 and the isolated DOC domain, but not
the isolated HECT domain, were co-immunopre-
cipitated from eYPF-CRAF cells. Bottom: loading
control for above, western blotted with a-GFP.
(D) Purified GST-DOC was added to HEK293 ly-
sates treated with increasing concentrations of
the HSP90 inhibitor AUY922 from 0, 100, 200, 400,
800, 1,600, and 3,200 nM and immunoprecipi-
tated. Endogenous CRAF and HSP90 were co-
immunoprecipitated, with increased yields at the
higher drug concentrations.of HSP90-linked degradative pathways for these proteins.
Therefore, we looked at the expression of HECTD3 in a range
of cell lines. Using a commercial HECTD3 antibody (ab173122,
Abcam) that recognizes an epitope close to the C terminus of
the protein, we performed western blots of cell extracts from
HEK293, COS7, U2OS, HT29, HCT116, and A549 cells (Fig-
ure 6A). Immunoreactive bands for proteins with molecular
weights 65 kDa and/or 97 kDa were visible, but the intensity
of these differed significantly between cell lines. The 97-kDa
band, consistent with the predicted molecular weight of the
full-length protein encoded by the HECTD3 gene (97,113 Da),
was clearly present in HEK293 cells. However, this was less
abundant in the other cell lines and totally absent in the cell ex-Cell Retracts from HT29 and HCT116 cells, in
which the 65-kDa band was the predom-
inant form. That the smaller band is de-
tected by antibodies to a C-terminal
epitope of HECTD3 suggests that it lacks
the N-terminal regions of the full-length
protein. The observed molecular weight
of this smaller species corresponds to
that predicted for the translated prod-
uct of a documented splice-variant
mRNA of HECTD3 (NCBI RefSeq
XM_011542140.1; predicted molecular
weight, 65,687 Da), in which exons 1
and 4 are missing, with translation initi-
ated from a start codon correspondingto Met 285 of the full-length protein. The predicted protein prod-
uct would start midway through the only part of the N-terminal
region of HECTD3 with a recognizable feature—an APC10/
DOC1-like domain that, we show, mediates interaction with its
CRAF substrate—and would certainly damage the folding and
functionality of that putative domain. Consistent with our positive
identification of the DOC domain as sufficient for association
with CRAF, we found that only the full-length 97-kDa form of
HECTD3, but not the 65-kDa N-terminally truncated form lacking
an intact DOC domain, was co-immunoprecipitated by EYFP-
CRAF from HEK293 cells (Figure 6B).
It is highly likely, therefore, that the shorter isoform found
in HCT116 and HT29 cells is not functional in mediatingports 19, 2515–2528, June 20, 2017 2523
Figure 6. HECTD3 Is Downregulated in
Cancer Cell Lines with Activated MAPK
Signaling
(A) Western blot of HECTD3 in lysates from
HEK293, COS7, and four human cancer cells
lines: U2OS, HT29, HCT116, and A549. Tumor cell
lines either lack immunoreactive protein or ex-
press a truncated isoform (also visible in HEK293)
that is recognized by the C-terminal epitope of the
a-HECTD3 antiserum. Themolecular weight of the
truncated product corresponds to that predicted
for an experimentally documented, alternatively
spliced isoform of HECTD3.
(B) Western blot of HECTD3 from lysates of
HEK293 cells expressing eYFP-CRAF. While both
97-kDa and 65-kDa HECTD3 isoforms are present
in the input, only the 97-kDa species corre-
sponding to the full-length protein is co-im-
munprecipitated with eYFP-CRAF.
(C) The truncated splice isoform of HECTD3 in
HCT116 cells is effectively knocked down by
siRNA, but unlike knockdown of the full-length
protein in HEK293 cells, this does not stabilize
endogenous CRAF protein to degradation trig-
gered by AUY922. This shows that the 65-kDa
isoform is not an active participant in CRAF ubiq-
uitylation and degradation.HSP90-directed CRAF degradation in those cells. Consistent
with this, while siRNA knockdown of HECTD3 in HCT116
cells (which harbor an activating KRAS mutation) substantially
decreased the intensity of the immunoreactive 65-kDa band, it
had no effect on the AUY922-triggered degradation of CRAF in
those cells (Figure 6C). Taken together, these data identify the
97-kDa isoform with the intact DOC domain as the active form
of HECTD3 and suggest that HCT116 cells, which appear to
lack the immunoreactive 97-kDa band, also lack functional
HECTD3 E3 ubiquitin ligase activity toward CRAF.2524 Cell Reports 19, 2515–2528, June 20, 2017DISCUSSION
Client protein degradation is the mecha-
nism by which inhibitors of the HSP90
chaperone achieve their therapeutic ef-
fect, particularly in cancer cells whose
growth and/or survival is dependent on
HSP90-dependent signaling pathways
such as the MAPK cascade (Acquaviva
et al., 2014; Garon et al., 2013; Smyth
et al., 2014). Whether activated by muta-
tions in KRAS or BRAF, tumorigenic
MAPK signaling requires CRAF, which,
in turn, depends, for both its cellular
stability and activity, on its association
with the CDC37-HSP90 molecular chap-
erone system (Grammatikakis et al.,
1999; Pearl, 2005).
As with other HSP90 client protein ki-
nases, impairment of HSP90 function by
pharmacological inhibition of its ATPaseactivity promotes CRAF ubiquitylation and degradation (Eccles
et al., 2008; Mimnaugh et al., 1996; Schulte et al., 1995), but
the mechanism by which this occurs is poorly understood. In
particular, the identity (or identities) of the E3 ubiquitin ligase
(or ligases) responsible for specifically recognizing and modi-
fying the client protein substrates is uncertain. Previous studies
demonstrated a role for CUL5-based complexes in HSP90-in-
hibitor-dependent kinase degradation in cancer cells such as
HT29 and HCT116 (Ehrlich et al., 2009; Samant et al., 2014)
that was surprisingly independent of the TCEB2-TCEB1 (Elongin
B-Elongin C) proteins that physically link CUL5 to the SOCS sub-
strate specificity adaptors of that system (Lydeard et al., 2013).
We also observed involvement of CUL5, in our screen, in non-
cancerous HEK293 cells, but this appears to be more conven-
tional in behavior and dependent on TCEB2-TCEB1.
Here, we have identified HECTD3 as a novel player in the
degradation of CRAF, as well as other HSP90 protein kinase cli-
ents. HECTD3 is specific for degradation following the inhibition
of HSP90’s ATPase activity, but it does not appear to make a
major contribution to general CRAF homeostasis or to the chap-
erone-deprivation pathway triggered by the kinase inhibitor
blockade of CDC37 binding (Polier et al., 2013).
Full-length 97-kDa HECTD3 protein was readily detectable in
HEK293 cells, but not in tumor cells. HT29 and HCT116 cells ex-
press a 65-kDa alternatively spliced isoform, also detectable in
HEK293 cells, that is inactive in CRAF degradation. Alteration
in mRNA splicing patterns is emerging as a significant mecha-
nism in the progressive acquisition of cancer ‘‘hallmarks’’ by
the evolving tumor cell (Oltean and Bates, 2014). Sustaining
adequate CRAF protein levels in a tumor cell addicted to
MAPK-pathway activation would certainly be favored by adap-
tive downregulation of a targeted degradation pathway, and
alternative splicing of a key E3 ubiquitin ligase to a non-functional
isoform, as we observed in the HCT116 cells, would be an effec-
tive mechanism to achieve this. HECTD3 may, therefore, have a
tumor-suppressive function, controlling the amount of CRAF
protein that can be activated through the HSP90 system and
thereby limiting MAPK pathway activation.
Relatively little is known about the biochemistry of HECTD3,
which has a unique architecture among HECT-domain E3 ubiq-
uitin ligases (Marı´n, 2010; Rotin and Kumar, 2009) and is poorly
characterized at a functional level, although highly conserved
in metazoa. HECTD3 has been implicated in the degradation of
a handful of proteins, none of which are protein kinases and/or
known HSP90 clients (Li et al., 2013a, 2013b; Yu et al., 2008;
Zhang et al., 2009), but several of these studies utilized overex-
pressed protein where specificity may be impaired and/or
have monitored cellular phenomena that could be downstream
of HECTD3’s presumed primary activity as an E3 ligase. We
show here the direct involvement of HECTD3 in the degradation
of CRAF and other kinases, confirmed by knockdown rather than
overexpression.
Our data show that HECTD3 associates strongly with HSP90,
CDC37, and CRAF in response to inhibition of the HSP90
ATPase cycle and likely forms a complex with these proteins.
Consistent with this, HECTD3 was detected as a potential
HSP90 interactor in a large-scale proximity screen (Table S1
in Taipale et al., 2012); interestingly, CUL5 was not detected
in that screen. Some HECT-domain E3 ligases recognize their
substrates via interaction domains within the same polypeptide
chain, while others utilize separate adaptor proteins to mediate
substrate interactions in an manner analogous to that of CRL
E3 ligases (Rotin and Kumar, 2009). HECTD3 contains a DOC
domain structurally related to the APC10 subunit that acts as
a degron recognition factor in the APC/C E3 ligase complex
(da Fonseca et al., 2011). We show here that this domain,
which is disrupted in the alternative spliced inactive isoforms
found in CRAF-dependent tumor cell lines, is both necessaryand sufficient for HECTD3 to associate with CRAF and with
HSP90.
Key to understanding the process of HSP90-mediated degra-
dation of client proteins such as CRAF by HECTD3 and other
systems will be the identification of the specific degron recog-
nized by the E3 ligase. Whether this is provided by HSP90, the
kinase-specific co-chaperone CDC37, the client kinase itself,
or some combination of these, remains to be determined.
EXPERIMENTAL PROCEDURES
Expression Plasmid
The gene for the full-length human CRAF was synthesized and cloned into
pEYFP-C1 by GenScript as an XhoI-BamHI fragment. Codons were optimized
for baculovirus expression.
Recombinant HECTD3 Expression and Purification
Full-length human HECTD3 was cloned as a BamHI-HindII fragment into
pFastbac1 and expressed as a His-tagged fusion in Sf9 cells. The DOC
domain (amino acid residues 219–398) and the HECT domain (amino acid res-
idues 512–861) of HECTD3 were cloned as NdeI-HindIII fragments into p3E
(Antony Oliver, University of Sussex) and expressed in E. coli. His6-tagged
HECTD3 was purified by TALON metal affinity chromatography equilibrated
in 50mMHEPES (pH 7.5), containing 500 mMNaCl. Eluted protein was further
purified by size exclusion chromatography using Superdex 200 HR equili-
brated in 50 mM Tris, 500 mM NaCl, 1 mM EDTA, and 1 mM DTT (pH 7.5)
and Q-Sepharose ion exchange chromatography. GST-DOC and GST-HECT
domains were purified using Glutathione Sepharose 4B (GE Healthcare) equil-
ibrated in 20 mM Tris, 140 mM NaCl, 1 mM EDTA, and 1 mM DTT (pH 7.4) and
subsequently by Superdex 75 or 200 HR size exclusion chromatography, as
appropriate. Both GST-DOC and GST-HECT domain constructs were further
purified using Q-Sepharose ion-exchange chromatography.
In Vitro Binding Assays
HEK293 cells, or HEK293 cells expressing eYFP or eYFP-CRAF, were lysed in
25mMHEPES (pH 7.8) containing 0.5 mMEDTA, 150mMNaCl, 10% glycerol,
0.5% Triton-100, and protease inhibitors for 1 hr at 4C. The cell lysate was
clarified by centrifugation at 16,000 3 g for 25 min at 4C. Equal amounts of
the supernatant (300–500 mL) were then transferred into Eppendorf tubes,
and 60 mg His-HECTD3, GST-DOC, and GST-HECT were added into
HEK293 cell lysate or cell lysate containing expressed eYFP, as controls, or
eYFP-CRAF. The cell lysates were then incubated for 2 hr at 4C. Meanwhile,
GFP-Trap resin (Chromotek, gta-10) was washed three times with 25 mM
HEPES (pH 7.8) containing 0.5 mM EDTA, 150 mM NaCl, 10% glycerol, and
protease inhibitors and then blocked by incubation with HEK293 cell lysate
to reduce subsequent non-specific binding of protein. 30 mL of the pretreated
beads were then added to cell lysates, and their ability to co-immunoprecipi-
tate eYFP-CRAF and HECTD3 was analyzed by western blotting.
Essentially, the same procedure was used with cell lysate pretreated for
120 min at 4C with 0, 100, 200, 400, 800, 1,600 or 3,200 nM AUY922. In these
experiments, pretreated GST-Trap resin (Chromotek, sta-200) was used, and
co-immunoprecipitations of CRAF and HSP90 were analyzed by western
blotting.
Culture and Cell Line Generation
HCT116 human colorectal carcinoma and HT29 human colorectal adenocar-
cinoma cell lines were a kind gift from Paul Workman, (The Institute of Cancer
Research). Both HCT116 and HT29 cells were grown in DMEM (Life Technol-
ogies, 21969-035) supplemented with 10% fetal calf serum (FCS) (home-
made), 1 mmol/L non-essential amino acid (Life Technologies, 11140-035),
and 1 mmol/L L-glutamine (Life Technologies, 25200-056). HEK293, COS7,
U2OS, and A549 cell lines were obtained from the Genome Damage and Sta-
bility Centre, University of Sussex. These cell lines were cultured in DMEM
supplemented with 10% FCS and 1 mmol/L L-glutamine. All cells were grown
at 37C with a 5% CO2 humidified atmosphere.Cell Reports 19, 2515–2528, June 20, 2017 2525
Stable HEK293 cell lines expressing eYFP-CRAF were generated by trans-
forming cells with peYFP-CRAF using TurboFect (Thermo Fisher, R0531) as
the transfection reagent. G418 was used to select stable cell lines and main-
tained on the standard DMEM described earlier.
Western Blots and Antibodies
Cells were lysed with 23 NuPAGE LDS Sample Buffer (Life Technologies,
NP0007). Cell lysates were then boiled at 100C for 10–15 min. All samples
were then loaded onto SDS-polyacrylamide gels (Life Technologies, NuPAGE
4–12% Bis-Tris Protein Gel, NP0321BOX).
Western blot was carried out on a Bio-Rad Trans-Blot Semi-Dry apparatus
using transfer buffer (25 mMTris [pH 8.5], 192mM glycine, and 20%methanol)
for 50–70 min at 210 V and 120 mA on a nitrocellulose membrane. The mem-
brane was then pre-blocked by incubation in 5%milk powder in PBS (137 mM
NaCl, 2.7 mM KCl, 10 mM Na2PO4, and KH2PO4 [pH 7.4]) and during the incu-
bation with antibodies. Primary antibodies were incubated with the membrane
overnight and washed three times with PBS containing 0.1% Tween 20. The
membrane was then incubated with the secondary antibody for 1–2 hr with
2% milk powder in PBS. The primary antibodies used were: a-CRAF (SC-
133 and SC-7267), a-BRAF (SC-5284), a-PDK1 (SC-7140), a-CDK4 (SC-
601), and a-Ub (SC-8017) from Santa Cruz Biotechnology; a-HECTD3
(ab173122), a-biotin (ab53494), a-LKB1 (ab15095), a-RET (ab134100),
and a-HSP90 (ab13492) from Abcam; a-phospho-p44/42 MAPK (9101S),
a-HER2/ErbB2 (2242L), a-GFP (2555S), and a-SRC (2108S) from Cell
Signaling; a-GAPDH (MA5-15738) from Thermo Fisher; and a-MASTL (A302-
190A) from Bethyl Laboratories. Primaries were detected using commercially
available HRP (horseradish peroxidase)-conjugated secondary antibodies and
visualized either on film or on an ImageQuant LAS500 (GE Healthcare).
Immunofluorescence Staining
Cells were grown to a 50%–75% confluency on coverslips (Thermo Scientific,
A67761333) in six-well plates. These were then washed three times with warm
PBS buffer, fixed with 4% paraformaldehyde in PBS for 15 min, and subse-
quently permeabilized with 0.3% Triton X-100/PBS for 10 min. Following
this, cells were blocked for 20 min with BlockAid Blocking Solution (Life Tech-
nologies, B10710) and then incubated for 1 hr with the appropriate primary
antibody diluted in blocking solution. Slips were subsequently washed and
incubated with the correct secondary antibody labeled with a corresponding
Alexa Fluor fluorophore. Finally, cells were stained with DAPI prior to imaging.
Fluorescence Degradation Assay
The fluorescence of eYFP-tagged full-length human CRAF in HEK293 cells
was measured on a POLARstar Omega plate reader with an excitation wave-
length of 485 nm and an emission wavelength of 520 nm. The fluorescence in-
tensity was recorded at 0, 4, 8, and 12 hr after AUY922 treatment.
Azide and Alkyne Reaction Pulse Labeling for Newly Synthesized
Protein
HEK293 cells stably expressing EYFP-CRAF were transfected with siRNA and
grown for 72 hr. All cell samples were then washed twice with warm PBS and
cultured in L-methionine-free DMEM (Invitrogen, 21013-024) for 1 hr. Subse-
quently, the cells were washed twice with warm PBS, before labeling with
30 mM Click-iT AHA (L-azidohomoalanine) (Invitrogen, C10102) for 3 hr, and
then washed with warm PBS and regrown in DMEM medium for 24 hr.
Samples were collected without trypsinization, and cell pellets were frozen
in liquid nitrogen and stored at 80C. As required, cell samples were lysed
in buffer containing 0.5 mM EDTA, 25 mM HEPES (pH 7.8), 150 mM NaCl,
10% glycerol, 0.5% Triton-100, and 1/100 protease inhibitor for 1 hr at 4C,
and the lysate was clarified by centrifugation at 16,100 3 g for 25 min at
4C. 50 mL of the supernatant (up to 200 mg of protein) containing the AHA-
labeled protein sample was used for the AHA-azide and biotin alkyne (Thermo
Fisher, B10185) conjugation in the absence of DTT, which is a potent inhibitor
of the reaction, using the Click-iT Protein Reaction Buffer Kit (Invitrogen,
C10276).
Conjugation was performed by rolling the sample for 20min at room temper-
ature. Subsequently, the buffer solution of the sample was exchanged on a PD
SpinTrap G-25 column (GE, 28-9180-04) equilibrated with 0.5 mM EDTA,2526 Cell Reports 19, 2515–2528, June 20, 201725 mM HEPES (pH 7.8), 150 mM NaCl, 10% glycerol, and 1/100 protease in-
hibitor. The labeled sample was used in GFP-Trap (Chromotek, gta-10) pull-
down experiments. The results were finally analyzed by western blot analysis.
PLA
Wild-type HEK293 cells were fixed with 4% paraformaldehyde and permeabi-
lized with 0.3% Triton X-100/PBS for 10 min. The ligation experiment was per-
formed according to the manufacturer’s instructions using the Duolink In Situ
Red Starter Kit (Sigma-Aldrich, DUO92101). Primary antibodies used were:
a-CRAF (SC-133 or SC-7267, Cell Signaling), a-HECTD3 (ab173122, Abcam),
and HSP90 (ab13492, Abcam).
Microscopy and Imaging Processing
All sample images from immunofluorescence assays and PLA were captured
by a Leica TCS SP8 confocal microscope. ImageJ or Fiji (for Mac) was used to
process the images.
siRNA Screen
siRNA screening was conducted using the RTF SMARTpool siRNA Library -
Human Ubiquitin Conjugation Subset 1 (Dharmacon), consisting of two
siRNA-coated plates (H-105615, Lot 12115). Plates were used to reverse-
transfect cells at 50 nM final siRNA concentration into optical imaging plates.
72 hr after transfection, eYFP-CRAF degradation was initiated by addition of
AUY922 for 8 hr. After incubation, cells were washed and fixed for 10min using
4% paraformaldehyde in PBS, permeabilized using 0.3% Triton in PBS, and
stained with 0.5 mg/mLDAPI in PBS for 15min. After final wash, all cell samples
were immediately imaged using the Olympus ScanR microscope at 103
magnification. Images were subsequently analyzed using ScanR Analysis
proprietary software. At minimum 10,000 cells were imaged per individual
sample, per experiment.
siRNA verification experiments were conducted in a similar format using
specific siRNAs (Table S2). siRNA controls used ON-TARGETplus Non-Tar-
geting Control siRNA #1 (Dharmacon).
Image Analysis
For analysis, the images were subjected to standardized background correc-
tion with a 50-pixel window and image segmentation analysis anchored to
imaged nuclei as main objects in order to get the total eYFP-CRAF intensity
per nucleus and nucleus-associated cytoplasmic region. To eliminate poten-
tial image segmentation artifacts, we included in the analysis only the cells
where the associated cell segment was smaller than 9,000 pixels—roughly
equivalent to the observed cell size on the raw image. We also excluded
high-DNA-content artifacts (>4 N), as they predominantly represented unre-
solved multi-nucleated cell aggregates. Thus, obtained, filtered data were
exported and analyzed using Microsoft Excel. All other immunofluorescence
experiments imaged and analyzed on the Olympus ScanR were subjected to
the same image-analysis protocol.
Statistical Analysis
eYFP-CRAF stabilization for experimental siRNA was calculated by the com-
parison of average fluorescence remaining after treatment with AUY922 for
12 hr with that remaining in AUY922-treated cells transfected with a control
siRNA. Z scores for each target gene were calculated from the mean and
SD of stabilization scores for the full-screen, omitting controls.
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